Table 1.
Clinical characteristics of the patients at baseline
| Parameter | Evaluable population (total, n = 83) n (%) |
|---|---|
| Age, years | |
| Median | 56 |
| Range | 23-81 |
| BRCA1/2 status | |
| Pathogenic variant | 15 (18) |
| Wild type | 53 (64) |
| Untested | 15 (18) |
| ECOG performance status | |
| 0 | 74 (89) |
| 1 | 9 (11) |
| Prior neoadjuvant chemotherapy | |
| Anthracycline | 18 (22) |
| Taxane | 18 (22) |
| Platinum salts | 2 (2) |
| Prior adjuvant chemotherapy | |
| Anthracycline | 48 (58) |
| Taxane | 48 (58) |
| Platinum salts | 4 (5) |
| Prior lines of chemotherapy for metastatic disease | |
| 0 | 66 (80) |
| 1a | 17 (20) |
| Sites of metastatic disease | |
| 1 site | 11 (13) |
| ≥2 | 66 (80) |
| Bone and visceral | 21 (25) |
| Visceral only | 57 (69) |
| Brain | 7 (8) |
ECOG, Eastern Cooperative Oncology Group; n, number.
a
Capecitabine, seven patients; carboplatin, six patients; vinorelbine/other, four patients.